According to the American Cancer Society, the odds that a person will develop lung cancer is about 1 in 19. Also, more than ¾ of all lung cancers are non-small cell lung cancer patients.
Pancreatic Cancer Drug Shows Potential in Lung Cancer
A drug recently approved for treatment of pancreatic cancer may show promising result against a specific type of lung cancer as well, a new study finds. The study has been published in the New England Journal of Medicine. It was funded by Revolution Medicines, which will be selling dadaxonrasib under the brand name Rasonque.
Early Clinical Trial Shows Tumor Reduction
In the early phase clinical trial, researchers gave 136 non-small cell lung cancer patients daily doses of the drug called daraxonrasib, for three weeks at a time. The pill was found to be safe and was able to reduce tumor burden in over 30% of the patients. Among those who received a lower dose, 31% patients saw reduction in tumor. The middle range dose group saw 34% while highest dose group saw 37% of patients with reduced tumor.
Side Effects Reported During the Study
It was also found that all participants reported side effects with severe ones in 54% of individuals. The common side effects included rash, nausea, vomiting and diarrhea. But some patients also experienced mucositis, pneumonia and low blood counts.
Further Lung Cancer Trials May Be Needed
The results could hold promise for leading cause of cancer deaths worldwide. FDA will likely request further late-stage clinical trials with more participants before evaluating the drug’s potential for approval as a treatment for lung cancer.
FDA Approval for Pancreatic Cancer
Last week, this drug, daraxonrasib, has been approved by FDA for treatment of those with metastatic pancreatic adenocarcinoma who have received at least one prior systematic therapy or cancer treatments that target the entire body.
The information shared in this blog is for educational purposes only. You should always consult with your healthcare professional for any medical issues.
Subscribe to our newsletter or follow us on Facebook or X today to stay informed and never miss an update!
FAQ
Can a pancreatic cancer drug treat lung cancer?
Early research suggests some pancreatic cancer drugs may have potential against specific lung cancers, but more trials are needed.
What is daraxonrasib used for?
Daraxonrasib is a targeted cancer drug being studied for cancers involving specific molecular changes.
Did the drug reduce lung cancer tumors?
Yes. The early trial reported tumor reductions in some patients with NSCLC.
Is daraxonrasib approved for lung cancer?
Further clinical trials may be needed before regulators consider a lung cancer indication.
What is NSCLC?
NSCLC stands for non-small cell lung cancer and accounts for most lung cancer cases.